The aspirin cardiovascular/gastrointestinal risk calculator ‐ a tool to aid clinicians in practice
Summary Background Assessment of both GI and CV risks vs. the benefits of low‐dose aspirin for individual patients can be difficult in clinical practice. Aim To develop a tool to estimate CV and GI risks to facilitate the clinical decision‐making process. Methods We constructed risk‐ratio estimation...
Gespeichert in:
Veröffentlicht in: | Alimentary pharmacology & therapeutics 2013-04, Vol.37 (7), p.738-748 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 748 |
---|---|
container_issue | 7 |
container_start_page | 738 |
container_title | Alimentary pharmacology & therapeutics |
container_volume | 37 |
creator | Lanas, A. Polo‐Tomás, M. Casado‐Arroyo, R. |
description | Summary
Background
Assessment of both GI and CV risks vs. the benefits of low‐dose aspirin for individual patients can be difficult in clinical practice.
Aim
To develop a tool to estimate CV and GI risks to facilitate the clinical decision‐making process.
Methods
We constructed risk‐ratio estimations and determined the incidence of CV events and upper GI complications according to the presence of different risk factors. For upper GI complications we assumed a baseline incidence of 1 case/1000‐persons‐year, a twofold increased risk with low‐dose aspirin, and estimated a 60% GI risk reduction with proton pump inhibitors (PPI) co‐therapy and a 60% risk reduction with H. pylori eradication in patients with a history of peptic ulcer.
Results
The calculator can be found at http://www.asariskcalculator.com. In patients with low CV risk the number of GI complications induced by low‐dose aspirin may be greater than the number of CV events prevented. In patients with high CV risk, low‐dose aspirin is recommended, but the number of GI complications induced may still overcome the CV events saved. The use of PPI reduces the number of complication events induced by low‐dose aspirin, but the number of CV events saved may still be offset by the number of GI complications induced in patients at very high GI risk.
Conclusions
There are many clinical situations where the number of potential upper GI complications induced by low‐dose aspirin may exceed the number of potentially prevented CV events. A risk calculator should guide physicians in choosing appropriate therapy and maximise the aspirin benefit. |
doi_str_mv | 10.1111/apt.12240 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1314894102</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1314894102</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3900-56da56dd3cf746de044426bbb3d2affc5b0d3c30d4b738a21d96435d427f97193</originalsourceid><addsrcrecordid>eNp1kEtOwzAQhi0EoqWw4ALIGyRYpPUrSbOsKl5SJViUdTSxHTC4SbATUHccgTNyElxSYMVIHi_m0z-jD6FjSsY01ASadkwZE2QHDSlP4ogRnuyiIWFJFrEp5QN04P0TISRJCdtHA8YF5dlUDJFaPmoMvjHOVFiCU6Z-BS87C27yAL51tala7VtTgcXO-OcA2c24rR3-fP_AgNu6tqFhMApLayojDVQeh7zGgWyN1IdorwTr9dH2H6H7y4vl_Dpa3F7dzGeLSPKMkChOFISnuCxTkShNhBAsKYqCKwZlKeOChBknShQpnwKjKksEj5VgaZmlNOMjdNbnNq5-6cLV-cp4qa2FStedzymnYpoJSlhAz3tUutp7p8u8cWYFbp1Tkm-k5kFq_i01sCfb2K5YafVL_lgMwOkWCOrAlg4qafwfl1IRc77hJj33Zqxe_78xn90t-9VfZFKPVw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1314894102</pqid></control><display><type>article</type><title>The aspirin cardiovascular/gastrointestinal risk calculator ‐ a tool to aid clinicians in practice</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><creator>Lanas, A. ; Polo‐Tomás, M. ; Casado‐Arroyo, R.</creator><creatorcontrib>Lanas, A. ; Polo‐Tomás, M. ; Casado‐Arroyo, R.</creatorcontrib><description>Summary
Background
Assessment of both GI and CV risks vs. the benefits of low‐dose aspirin for individual patients can be difficult in clinical practice.
Aim
To develop a tool to estimate CV and GI risks to facilitate the clinical decision‐making process.
Methods
We constructed risk‐ratio estimations and determined the incidence of CV events and upper GI complications according to the presence of different risk factors. For upper GI complications we assumed a baseline incidence of 1 case/1000‐persons‐year, a twofold increased risk with low‐dose aspirin, and estimated a 60% GI risk reduction with proton pump inhibitors (PPI) co‐therapy and a 60% risk reduction with H. pylori eradication in patients with a history of peptic ulcer.
Results
The calculator can be found at http://www.asariskcalculator.com. In patients with low CV risk the number of GI complications induced by low‐dose aspirin may be greater than the number of CV events prevented. In patients with high CV risk, low‐dose aspirin is recommended, but the number of GI complications induced may still overcome the CV events saved. The use of PPI reduces the number of complication events induced by low‐dose aspirin, but the number of CV events saved may still be offset by the number of GI complications induced in patients at very high GI risk.
Conclusions
There are many clinical situations where the number of potential upper GI complications induced by low‐dose aspirin may exceed the number of potentially prevented CV events. A risk calculator should guide physicians in choosing appropriate therapy and maximise the aspirin benefit.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/apt.12240</identifier><identifier>PMID: 23413984</identifier><language>eng</language><publisher>Oxford: Blackwell</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Algorithms ; Aspirin - administration & dosage ; Aspirin - adverse effects ; Biological and medical sciences ; Cardiovascular Diseases - chemically induced ; Cardiovascular Diseases - prevention & control ; Digestive system ; Dose-Response Relationship, Drug ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Gastrointestinal Hemorrhage - chemically induced ; Gastrointestinal Hemorrhage - prevention & control ; Gastrointestinal Tract - drug effects ; Humans ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Platelet Aggregation Inhibitors - administration & dosage ; Platelet Aggregation Inhibitors - adverse effects ; Proton Pump Inhibitors - administration & dosage ; Risk Assessment - methods ; Risk Factors ; Young Adult</subject><ispartof>Alimentary pharmacology & therapeutics, 2013-04, Vol.37 (7), p.738-748</ispartof><rights>2013 Blackwell Publishing Ltd</rights><rights>2014 INIST-CNRS</rights><rights>2013 Blackwell Publishing Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3900-56da56dd3cf746de044426bbb3d2affc5b0d3c30d4b738a21d96435d427f97193</citedby><cites>FETCH-LOGICAL-c3900-56da56dd3cf746de044426bbb3d2affc5b0d3c30d4b738a21d96435d427f97193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fapt.12240$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fapt.12240$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27145334$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23413984$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lanas, A.</creatorcontrib><creatorcontrib>Polo‐Tomás, M.</creatorcontrib><creatorcontrib>Casado‐Arroyo, R.</creatorcontrib><title>The aspirin cardiovascular/gastrointestinal risk calculator ‐ a tool to aid clinicians in practice</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary
Background
Assessment of both GI and CV risks vs. the benefits of low‐dose aspirin for individual patients can be difficult in clinical practice.
Aim
To develop a tool to estimate CV and GI risks to facilitate the clinical decision‐making process.
Methods
We constructed risk‐ratio estimations and determined the incidence of CV events and upper GI complications according to the presence of different risk factors. For upper GI complications we assumed a baseline incidence of 1 case/1000‐persons‐year, a twofold increased risk with low‐dose aspirin, and estimated a 60% GI risk reduction with proton pump inhibitors (PPI) co‐therapy and a 60% risk reduction with H. pylori eradication in patients with a history of peptic ulcer.
Results
The calculator can be found at http://www.asariskcalculator.com. In patients with low CV risk the number of GI complications induced by low‐dose aspirin may be greater than the number of CV events prevented. In patients with high CV risk, low‐dose aspirin is recommended, but the number of GI complications induced may still overcome the CV events saved. The use of PPI reduces the number of complication events induced by low‐dose aspirin, but the number of CV events saved may still be offset by the number of GI complications induced in patients at very high GI risk.
Conclusions
There are many clinical situations where the number of potential upper GI complications induced by low‐dose aspirin may exceed the number of potentially prevented CV events. A risk calculator should guide physicians in choosing appropriate therapy and maximise the aspirin benefit.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Algorithms</subject><subject>Aspirin - administration & dosage</subject><subject>Aspirin - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular Diseases - chemically induced</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Digestive system</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Gastrointestinal Hemorrhage - chemically induced</subject><subject>Gastrointestinal Hemorrhage - prevention & control</subject><subject>Gastrointestinal Tract - drug effects</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Platelet Aggregation Inhibitors - administration & dosage</subject><subject>Platelet Aggregation Inhibitors - adverse effects</subject><subject>Proton Pump Inhibitors - administration & dosage</subject><subject>Risk Assessment - methods</subject><subject>Risk Factors</subject><subject>Young Adult</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kEtOwzAQhi0EoqWw4ALIGyRYpPUrSbOsKl5SJViUdTSxHTC4SbATUHccgTNyElxSYMVIHi_m0z-jD6FjSsY01ASadkwZE2QHDSlP4ogRnuyiIWFJFrEp5QN04P0TISRJCdtHA8YF5dlUDJFaPmoMvjHOVFiCU6Z-BS87C27yAL51tala7VtTgcXO-OcA2c24rR3-fP_AgNu6tqFhMApLayojDVQeh7zGgWyN1IdorwTr9dH2H6H7y4vl_Dpa3F7dzGeLSPKMkChOFISnuCxTkShNhBAsKYqCKwZlKeOChBknShQpnwKjKksEj5VgaZmlNOMjdNbnNq5-6cLV-cp4qa2FStedzymnYpoJSlhAz3tUutp7p8u8cWYFbp1Tkm-k5kFq_i01sCfb2K5YafVL_lgMwOkWCOrAlg4qafwfl1IRc77hJj33Zqxe_78xn90t-9VfZFKPVw</recordid><startdate>201304</startdate><enddate>201304</enddate><creator>Lanas, A.</creator><creator>Polo‐Tomás, M.</creator><creator>Casado‐Arroyo, R.</creator><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201304</creationdate><title>The aspirin cardiovascular/gastrointestinal risk calculator ‐ a tool to aid clinicians in practice</title><author>Lanas, A. ; Polo‐Tomás, M. ; Casado‐Arroyo, R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3900-56da56dd3cf746de044426bbb3d2affc5b0d3c30d4b738a21d96435d427f97193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Algorithms</topic><topic>Aspirin - administration & dosage</topic><topic>Aspirin - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular Diseases - chemically induced</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Digestive system</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Gastrointestinal Hemorrhage - chemically induced</topic><topic>Gastrointestinal Hemorrhage - prevention & control</topic><topic>Gastrointestinal Tract - drug effects</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Platelet Aggregation Inhibitors - administration & dosage</topic><topic>Platelet Aggregation Inhibitors - adverse effects</topic><topic>Proton Pump Inhibitors - administration & dosage</topic><topic>Risk Assessment - methods</topic><topic>Risk Factors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lanas, A.</creatorcontrib><creatorcontrib>Polo‐Tomás, M.</creatorcontrib><creatorcontrib>Casado‐Arroyo, R.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lanas, A.</au><au>Polo‐Tomás, M.</au><au>Casado‐Arroyo, R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The aspirin cardiovascular/gastrointestinal risk calculator ‐ a tool to aid clinicians in practice</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2013-04</date><risdate>2013</risdate><volume>37</volume><issue>7</issue><spage>738</spage><epage>748</epage><pages>738-748</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Summary
Background
Assessment of both GI and CV risks vs. the benefits of low‐dose aspirin for individual patients can be difficult in clinical practice.
Aim
To develop a tool to estimate CV and GI risks to facilitate the clinical decision‐making process.
Methods
We constructed risk‐ratio estimations and determined the incidence of CV events and upper GI complications according to the presence of different risk factors. For upper GI complications we assumed a baseline incidence of 1 case/1000‐persons‐year, a twofold increased risk with low‐dose aspirin, and estimated a 60% GI risk reduction with proton pump inhibitors (PPI) co‐therapy and a 60% risk reduction with H. pylori eradication in patients with a history of peptic ulcer.
Results
The calculator can be found at http://www.asariskcalculator.com. In patients with low CV risk the number of GI complications induced by low‐dose aspirin may be greater than the number of CV events prevented. In patients with high CV risk, low‐dose aspirin is recommended, but the number of GI complications induced may still overcome the CV events saved. The use of PPI reduces the number of complication events induced by low‐dose aspirin, but the number of CV events saved may still be offset by the number of GI complications induced in patients at very high GI risk.
Conclusions
There are many clinical situations where the number of potential upper GI complications induced by low‐dose aspirin may exceed the number of potentially prevented CV events. A risk calculator should guide physicians in choosing appropriate therapy and maximise the aspirin benefit.</abstract><cop>Oxford</cop><pub>Blackwell</pub><pmid>23413984</pmid><doi>10.1111/apt.12240</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0269-2813 |
ispartof | Alimentary pharmacology & therapeutics, 2013-04, Vol.37 (7), p.738-748 |
issn | 0269-2813 1365-2036 |
language | eng |
recordid | cdi_proquest_miscellaneous_1314894102 |
source | MEDLINE; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection) |
subjects | Adolescent Adult Aged Aged, 80 and over Algorithms Aspirin - administration & dosage Aspirin - adverse effects Biological and medical sciences Cardiovascular Diseases - chemically induced Cardiovascular Diseases - prevention & control Digestive system Dose-Response Relationship, Drug Female Gastroenterology. Liver. Pancreas. Abdomen Gastrointestinal Hemorrhage - chemically induced Gastrointestinal Hemorrhage - prevention & control Gastrointestinal Tract - drug effects Humans Male Medical sciences Middle Aged Pharmacology. Drug treatments Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - adverse effects Proton Pump Inhibitors - administration & dosage Risk Assessment - methods Risk Factors Young Adult |
title | The aspirin cardiovascular/gastrointestinal risk calculator ‐ a tool to aid clinicians in practice |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T21%3A21%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20aspirin%20cardiovascular/gastrointestinal%20risk%20calculator%20%E2%80%90%20a%20tool%20to%20aid%20clinicians%20in%20practice&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Lanas,%20A.&rft.date=2013-04&rft.volume=37&rft.issue=7&rft.spage=738&rft.epage=748&rft.pages=738-748&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/apt.12240&rft_dat=%3Cproquest_cross%3E1314894102%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1314894102&rft_id=info:pmid/23413984&rfr_iscdi=true |